OMP and neoplasm: At first, drug development focused on disrupting WNT-driven tumor growth, including monoclonal antibodies to frizzled class receptor (FZD) receptors (e.g., OMP-54F28, OMP-18R5) (88), porcupine O-acyltransferase (PORCN) inhibitors (e.g., WNT974, RXC004, ETC1922159) (89), AXIN1 activators (e.g., Niclosamide, XAV939) (90), and β-catenin inhibitor (e.g., PRI724, PKF115-584) (91).